search
Front

Therapeutics co AtoxBio raises $3.25m

19 Dec, 2011 16:33
שלח תגובה במיילGali Weinreb

The company will use the funding for a Phase II clinical trial to test effectiveness of its treatment for necrotizing soft tissue infections.

Sources inform "Globes" that AtoxBio Ltd. has raised $3.5 million to finance a Phase II clinical trial for the effectiveness of its drug AB 103 for necrotizing soft tissue infections (NSTI).

The financing round was co-led by a private US-based investor and Dutch venture capital fund Esperante, which invests in drug development companies and whose other investments include Arno Therapeutics Inc. founded by an Israel - Arie Belldegrun. AtoxBio's latest financing round also includes an investment from an undisclosed US source.

AtoxBio has already begun its clinical trial at seven US medical centers with the trial scheduled for completion by the end of 2012. The drug being developed has orphan status because there are no other effective treatments available and thus qualifies to be fast tracked to the market and enjoy longer exclusivity if sells ever begin.

AtoxBio CEO Dan Teleman said that the company plans to complete a second closing of this financing round in early 2012.

Esperante managing director Dean Slagel said, "Atox Bio is one of the most exciting companies we have seen to date. AB103 shows promise across a broad range of indications, and this investment reflects our appreciation of the excellent scientific and clinical data package generated by the Atox Bio team."

Atox Bio will be included as one of the portfolio companies of Integra Holdings, a holding company formed by Yissum, the technology transfer company of the Hebrew University of Jerusalem.

AtoxBio was founded by Yissum based on the research of the Hebrew University's Prof. Raymond Kaempfer. The company has rased $4 million prior to the current round mainly from US philanthropist Newton Becker as well as government funds and other philanthropists.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) was once in talks to invest in AtoxBio but negotiations did not bear fruit.

Published by Globes, Israel business news - www.globes-online.com - on December 19, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

Avigdor Willenz credit: Intel Exclusive: Avigdor Willenz's Element Labs raises $50m

The Israeli startup is developing AI processors for inference, the stage in which AI models are activated after they have already been trained.

Ilya Sutskever credit: Cadya Levy SSI hiring dozens in Israel

AI company Safe Superintelligence is hiring many dozens of people in Tel Aviv, "Globes" has learned.

Johny Srouji credit: Amos Ben Gershom GPO Apple SVP leads senior delegation of execs to Israel

Jony Srouji: I am always filled with renewed energy and optimism about our shared achievements when I visit our R&D centers here.

Infinity Tower Tel Aviv credit: Courtesy Hagag Group French investors buy 2 Tel Aviv apartments for NIS 27.5m

The two apartments are in Hagag Group's Infinity Tower in the Summeil district.

El Al plane credit: Shutterstock El Al receives state approval to distribute dividend

The Israeli airline has now announced that it will be able to distribute up to 30% of net profit in 2025 and up to 40% in 2026-2028.

Israeli apartments Credit: Shutterstock Apartments sold and rented

A selection of recent real estate deals in Israel in Tel Aviv, Ramat Gan, Petah Tikva, Givat Shmuel, Tiberias and Dimona.

Mon: TASE reopens after holiday sharply higher

Energean and ICL led the gains today as only three stocks on the Tel Aviv 35 Index lost ground.

Foreign investment in TASE hits five-year high

Foreign investors have been flocking to the Tel Aviv Stock Exchange in recent weeks, the TASE research department tells "Globes."

Phoenix Investment House CEO Avner Hadad credit: Tommy Harpaz "The market has priced in all the bad things"

Phoenix Investment House CEO Avner Hadad says US markets could continue to fall, but that we are close to interesting territory for patient investors.

ZIM ship credit: ZIM Trump's tariffs torpedo ZIM's share price

ZIM's share price fell 16.4% on Wall Street on Thursday and a further 7.2% on Friday, closing with a market cap of $1.5 billion, wiping out all its gains in 2025.

Yoni Assia CEO eToro Credit: PR eToro defers IPO amid market turmoil

The online trading platform had planned to begin meetings with investors this week.

Caesarstone kitchen credit: Caesarstone Caesarstone bucks Nasdaq as tariffs boost potential

The Israeli quartz countertop manufacturer company has fallen on hard times due to Chinese rivalry but tariffs could boost its revenue.

Arkady Volozh credit: Shlomi Yosef Analysts see Israel-linked Nebius challenging CoreWeave

Nebius, founded by Yandex founder Arkady Volozh, operates in CoreWeave's AI server market, but is growing "more rationally", and has far less debt.

Highcon chairperson Shlomo Nimrodi credit: PR Packaging tech co Highcon winding down

The company, which numbers Benny Landa and JVP among its investors, is laying off most of its workforce, having lost 99.9% of its value since its flotation.

Tel Aviv credit: Shutterstock Tel Aviv slips in World's Wealthiest Cities ranking

Tel Aviv's position as one of the world's wealthiest cities took a big knock over the past year as it slipped from 42nd to 48th in investment advisors Henley & Co.'s "World's Wealthiest Cities" Top 50 ranking.

Accountant General Yali Rothenberg credit: Rafi Kutz Israel's fiscal deficit continues to narrow

The deficit narrowed in the twelve months to the end of March 2025, for the sixth consecutive month, Ministry of Finance accountant general Yali Rothenberg reported today.

President Donald Trump hosts Prime Minister Benjamin Netanyahu credit: Reuters Kevin Mohatt Israeli officials confident on US tariff concessions

Senior Israeli figures believe that concessions could be tied to progress on strategic regional political issues that are important to President Trump.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018